Biohaven fails OCD trial but pushes on to phase 3 regardless

A phase 2/3 trial of Biohaven Pharmaceutical’s troriluzole in obsessive-compulsive disorder (OCD) has missed its primary endpoint. Despite the setback, Biohaven is gearing up for a full phase 3 OCD program, pointing to other aspects of the midstage data to make its case.